{"url_path":"/sec/apge/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-025844-index.html","accession_number":"0001140361-26-025844","cik":"0001974640","ticker":"APGE","issuer_name":"Apogee Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-025844-index.html","primary_entity_key":"0001974640","primary_entity_name":"Apogee Therapeutics, Inc."},"word_count":145,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\n \n\nPress Release\n\n \n\nOn June 22, 2026, the Company and Guarantor issued a joint press release announcing their entry into the Merger Agreement, a copy of which is\nfiled as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe information contained in this Item 7.01 and the accompanying Exhibit 99.1 are furnished and shall not be deemed “filed” for purposes of\nSection 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it\nbe deemed incorporated by reference in any filing with the Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing."}